Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study
Cahn, Pedro, Dr, Pozniak, Anton L, MD, Mingrone, Horacio, MD, Shuldyakov, Andrey, MD, Brites, Carlos, MD, Andrade-Villanueva, Jaime F, MD, Richmond, Gary, MD, Buendia, Carlos Beltran, MD, Fourie, Jan, MD, Ramgopal, Moti, MD, Hagins, Debbie, MD, Felizarta, Franco, MD, Madruga, Jose, MD, Reuter, Tania, MD, Newman, Tamara, MD, Small, Catherine B, MD, Lombaard, John, MD, Grinsztejn, Beatriz, MD, Dorey, David, MMath, Underwood, Mark, PhD, Griffith, Sandy, PharmD, Min, Sherene, MD
Published in The Lancet (British edition) (24.08.2013)
Published in The Lancet (British edition) (24.08.2013)
Get full text
Journal Article
Cabotegravir plus rilpivirine, once a day, after induction with cabotegravir plus nucleoside reverse transcriptase inhibitors in antiretroviral-naive adults with HIV-1 infection (LATTE): a randomised, phase 2b, dose-ranging trial
Margolis, David A, Dr, Brinson, Cynthia C, MD, Smith, Graham H R, MD, de Vente, Jerome, MD, Hagins, Debbie P, MD, Eron, Joseph J, Prof, Griffith, Sandy K, PharmD, Clair, Marty H St, BS, Stevens, Marita C, MD, Williams, Peter E, PhD, Ford, Susan L, PharmD, Stancil, Britt S, BS, Bomar, Melinda M, BS, Hudson, Krischan J, PhD, Smith, Kimberly Y, MD, Spreen, William R, PharmD
Published in The Lancet infectious diseases (01.10.2015)
Published in The Lancet infectious diseases (01.10.2015)
Get full text
Journal Article